Journal: Blood Advances
Article Title: Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood
doi: 10.1182/bloodadvances.2024012613
Figure Lengend Snippet: Effect of FXIIa inhibition on contact pathway–initiated TG in PK-sufficient and -deficient WB. Representative curves of silica-initiated TG in Klkb1 +/+ (A) and Klkb1 – / – (B) mouse WB in the presence of increasing concentrations of the inhibitory anti-FXIIa antibody garadacimab. Quantification of TG lag time (C) and peak TG (D) in Klkb1 +/+ or Klkb1 – / – mouse WB in the presence of 50 μg/mL garadacimab or IgG control (n = 3-5 per group). Data presented as individual values with mean ± SD. Data analyzed with paired Student t tests comparing samples with and without inhibitor; ∗∗ P < .01. Gara, garadacimab; ns, not signficant.
Article Snippet: In some experiments, samples were supplemented with the small molecule PKa inhibitor berotralstat (MedChem Express, Monmouth Junction, NJ), an anti-FXIIa antibody (garadacimab/CSL-312 bio-similar; ATUM Bio, Newark, CA), an anti-PKa antibody (lanadelumab bio-similar; ProteoGenix USA, Miami, FL), an anti-TF antibody (1H1; Genentech, San Francisco, CA), or appropriate vehicle and immnuoglubulin G (IgG) controls.
Techniques: Inhibition, Control